BCX4430 / Zika | BCRX Message Board Posts

BioCryst Pharmaceuticals Inc.

  BCRX website

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10248 of 10529  at  10/16/2019 5:43:11 PM  by

map.here


BCX4430 / Zika

Research paper published today:
 
Computer-Assisted and Data Driven Approaches for Surveillance, Drug Discovery, and Vaccine Design for the Zika Virus
 
Received: 24 September 2019 / Accepted: 15 October 2019 / Published: 16 October 2019
BCX4430 an adenosine nucleoside analog has shown EC50 values in the low μg/mL range (3.8–18.2 μg/mL) in vitro, with favorable selective index values and found to be a selective inhibitor of viral RNA-dependent RNA polymerase (RdRp). The compound has also shown in vivo efficacy in AG129 mouse model of ZIKV. Treating the animals with BCX4430 (300 mg/kg/d) protected seven of eight mice from mortality induced by a Malaysian strain (P 6–740) of ZIKV [128]. This protective efficacy of BCX4430 encourages its further development on the basis of safety and better efficacy evaluations.
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 173
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10249 Re: BCX4430 / Zika frnktofini 3 10/17/2019 10:30:47 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...